Neutral Torrent Pharma; target of Rs 4970: Motilal Oswal

What happened

Motilal Oswal said Torrent Pharma's quarterly revenue and EBITDA, a measure of operating profit, beat expectations by 3% and 5%. Earnings matched estimates because the tax rate was higher than expected. The broker set a target price of Rs 4,970 with a Neutral rating.

Confirmed

Global impact / market context

A higher target price tells investors what profit the broker expects the stock to earn, while the Neutral rating suggests limited upside from current levels. Sales growth in chronic therapies, which are long-term treatments, and Semaglutide, a diabetes and weight drug, supports future revenue.

Analyst inference

Torrent outpaced the Indian pharmaceutical market and Brazil's branded generics market, which means copies of off-patent drugs sold under a brand name. That suggests share gains rather than just market growth, while the planned JB Pharma integration could add earnings if completed as expected.

Analyst inference

What to watch

1. Watch whether Torrent keeps beating the Indian pharmaceutical market through market share gains in chronic therapies and further scale-up of the Curatio portfolio, which the broker cited as growth drivers. Confirmed
2. Track progress on the JB Pharma integration, which the broker said could bring potential earnings benefits; any delay or extra cost would change that expectation. Proposed
3. Watch the tax rate, since a higher-than-expected rate kept earnings in line despite better sales, and any repeat would limit profit growth per share. Analyst inference

Evidence

• Original source link unavailable